Cancer Research
| 短名 | Cancer Res. |
| Journal Impact | 12.63 |
| 国际分区 | ONCOLOGY(Q1) |
| 期刊索引 | SCI Q1中科院 1 区 |
| ISSN | 0008-5472, 1538-7445 |
| h-index | 498 |
| 国内分区 | 医学(1区)医学肿瘤学(2区) |
| Top期刊 | 是 |
《癌症研究》是世界上被引用次数最多的癌症期刊。该杂志发表原创研究、评论和观点文章，对基础、临床前、临床、预防和流行病学研究的不同受众具有重要意义和广泛影响。癌症研究寻求提供病理生物学和转化影响的手稿，以告知癌症带来的个人、临床和社会问题。该杂志的主要内容包含在其主要小节中，重点关注分子和细胞病理学、肿瘤和干细胞生物学、治疗和靶点、微环境和免疫学、预防和流行病学以及集成系统和技术。
期刊主页投稿网址| 涉及主题 | 生物遗传学医学内科学化学生物化学癌症癌症研究基因病理免疫学细胞生物学肿瘤科外科乳腺癌有机化学内分泌学细胞凋亡细胞培养体外物理 |
| 出版信息 | 出版商: American Association for Cancer Research Inc.，出版周期: Semimonthly，期刊类型: journal |
| 基本数据 | 创刊年份: 1941，原创研究文献占比: 89.57%，自引率:0.80%， Gold OA占比: 27.89% |
| 平均审稿周期 | 网友分享经验：平均2.5月 |
| 平均录用比例 | 网友分享经验：约30% |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Precise In Situ Delivery of a Photo-enhanceable Inflammasome-Activating Nanovaccine Activates Anti-cancer Immunity
2024-9-17
Abstract C075: Ror2, a Novel Key Regulator Driving Cell Fate Decisions throughout Pancreatic Carcinogenesis
2024-9-15
Abstract B073: Organ-specific diversity of tumor immune microenvironment in metastatic pancreatic cancer
2024-9-15
Abstract A071: Inverse Biomarker Exploring Technology (IBMET) Mathematical Identification of Cancer-Specific Epitopes and Novel Targets (Biomarkers) from Big Data of Single-Domain Antibodies Recognizing Higher Structures
2024-9-15
Abstract IA-01: Targeting autophagy in pancreatic cancer
2024-9-15
Abstract PR-19: Cell polarity proteins as novel regulators of macropinocytosis
2024-9-15
Abstract B045: Sensitizing the PDAC tumor microenvironment to immune checkpoint therapies: characterization of a PDAC 3D model to decipher immune infiltration
2024-9-15
Abstract A075: Establishing the interaction mechanism of oncoprotein, Mucin1, and extracellular vesicle marker protein, Alix, in pancreatic cancer
2024-9-15
Abstract C008: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC
2024-9-15
Abstract PR-06: Dietary fats dictate pancreatic cancer fate via phospholipid saturation
2024-9-15
Abstract PR-12: The circadian rhythm gene Dec2 regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion
2024-9-15
Abstract B041: Fibroblast STAT3 Signaling in Pancreatic Cancer: Implications for Immunotherapy and Tumor Microenvironment Modulation
2024-9-15
Abstract A080: An analysis of outcomes in patients (pts) with advanced pancreatic cancer (PDAC) whose tumors harbor pathogenic BRCA1 or BRCA2 mutations based on gene mutation location
2024-9-15
Abstract B024: Multiplexed 3D atlas of state transitions and potential prognostic role of poly- ADP ribose glycohydrolase (PARG) in chronic pancreatitis and PDAC
2024-9-15
Abstract B066: An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs)
2024-9-15
Abstract A002: Phase II Trial of Vemurafenib + Sorafenib in Advanced KRAS Mutated Pancreas Cancer
2024-9-15
Abstract C076: Transcriptomic analyses of normal human pancreatic acinar cells reveal the presence of cancer subtypes that correlate with acinar ductal metaplasia
2024-9-15
Abstract B076: Morphological diversity predicts functional traits in pancreatic cancer
2024-9-15
Abstract C011: Targeting STAT3 overcomes PDAC resistance to EGFR/RAF1 inhibition leading to complete and durable tumor regression
2024-9-15
Abstract C049: Computational Methods for Central and Lipid Metabolism Networks Analysis to Reveals Flux Change in PDAC
2024-9-15
Abstract PR-05: Endocrine beta-cell stress promotes pancreatic ductal adenocarcinoma through endocrine-exocrine cell crosstalk
2024-9-15
Abstract C027: Efficacy advantages of a novel pan-RAS inhibitor, ADT-1004, over mutant- specific KRAS inhibitors for suppressing pancreatic tumor growth in murine models
2024-9-15
Abstract C039: Investigating ER stress responses in pancreatic ductal adenocarcinoma under lipid imbalance
2024-9-15
Abstract PR-15: Identifying synergistic combinations with KRAS inhibition in PDAC
2024-9-15
Abstract C019: A novel SDC1-targeted therapeutic antibody inhibits macropinocytosis and induces anti-tumor immunity in pancreatic cancer
2024-9-15
Abstract A062: Neurotropic fibroblast population increases following exposure to chemotherapy in pancreatic adenocarcinoma
2024-9-15
Abstract A074: Integrated clinical and single-cell profiling analysis reveals cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma
2024-9-15
Abstract A078: Functional screen for mediators of onco-mRNA translation specificity in pancreatic cancer
2024-9-15
Abstract B025: Surveillance outcome in individuals at high risk of pancreatic cancer
2024-9-15
Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models
2024-9-15
Abstract PR-08: Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis
2024-9-15
Abstract A045: Disrupting local immunosuppression through combination myCAF/myeloid targeting in pancreatic cancer
2024-9-15
Abstract A023: Patient-Derived Organoid Cultures for Personalized Therapies and Targeted Drug Screening Applications
2024-9-15
Abstract A035: 3D High-Density Collagen I Improves the Modeling of Aggressive Pancreatic Cancer
2024-9-15
Abstract A058: Primary cancer-associated fibroblasts alter tumor organoid chemosensitivity through epigenetic regulation
2024-9-15
Abstract B072: Pharmacological depletion of fibrinogen suppresses the growth of primary tumors and liver metastasis of pancreatic cancer
2024-9-15
Abstract C016: Pancreatitis-induced resistance to KRAS targeted therapy: The role of cellular plasticity and underlying mechanisms
2024-9-15
Abstract A022: Neoadjuvant ablative radiation downstages high-risk features and alters immune response in pancreatic cancer
2024-9-15
Abstract A012: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in Pancreatic Adenocarcinoma patients harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen
2024-9-15
Abstract C006: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes
2024-9-15
Abstract PR-04: Phase 2 Trial Testing The PARP Inhibitor Niraparib In Patients With Advanced Pancreatic Cancer with Pathogenic Variants In <i>BRCA 1, BRCA2, PALB2, ATM</i> and <i>CHEK2</i>
2024-9-15
Abstract B034: Myeloperoxidase limits tumor-associated neutrophils mediated immunosuppression in pancreatic cancer
2024-9-15
Abstract A066: nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer
2024-9-15
Abstract C055: Unraveling pancreatic cancer susceptibility at 5p15.33: Functional characterization of a novel VNTR element
2024-9-15
Abstract C079: Exploring acinar to ductal metaplasia in pancreatitis and precancerous contexts using FixNCut
2024-9-15
Abstract B092: PP2A activation alters macropinosome processing in pancreatic cancer cells leading to metabolic stress and cancer cell death
2024-9-15
Abstract A008: The effect of body mass index on Tumor Treating Fields (TTFields) intensity distribution in the abdomen: results of a simulation model study
2024-9-15
Abstract C052: Repurposing Statins to Target Gemcitabine Resistance in Pancreatic Cancer
2024-9-15
Abstract C001: Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy in Mice
2024-9-15
Abstract A021: <i>In silico</i> Prediction of Proteins Interacting with a Basal-like Pancreatic Cancer marker, RhoV, Using AlphaFold
2024-9-15
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远